Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KDN018
MIFTS: 71

Kidney Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Kidney Disease

About this section

MalaCards integrated aliases for Kidney Disease:

Name: Kidney Disease 12 3 15 17
Nephropathy 12 77 30 6 15
Kidney Diseases 44 45 74
Kidney Failure 44 17 74
Renal Failure 77 56 41
Abnormality of the Kidney 30 6
Renal Failure Adverse Event 74
Abnormal Renal Function 74
Kidney Dysfunction 56
Renal Anomaly 56
Renal Disease 56

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases Blood diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 34


Sources

Summaries for Kidney Disease

About this section
MedlinePlus : 44 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Kidney Disease, also known as nephropathy, is related to polycystic kidney disease 1 with or without polycystic liver disease and autosomal dominant polycystic kidney disease, and has symptoms including polyuria An important gene associated with Kidney Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways is A-beta Pathways: Plaque Formation and APP Metabolism. The drugs Perindopril and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver, and related phenotypes are cardiovascular system and digestive/alimentary

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 77 Kidney disease, or renal disease, also known as nephropathy, is damage to or disease of a kidney.... more...

Sources

Related Diseases for Kidney Disease

About this section

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2066)
# Related Disease Score Top Affiliating Genes
1 polycystic kidney disease 1 with or without polycystic liver disease 35.0 PKD1 PKD2 PKD2L1 PKHD1
2 autosomal dominant polycystic kidney disease 34.9 ACE ALB CST3 PKD1 PKD2 PKD2L1
3 polycystic kidney disease 4 with or without polycystic liver disease 34.9 PKD1 PKD2 PKHD1 TMEM67
4 polycystic kidney disease 34.8 ACE PKD1 PKD1L1 PKD1L2 PKD1L3 PKD2
5 polycystic kidney disease 2 with or without polycystic liver disease 34.8 PKD1 PKD1L1 PKD2 PKD2L1 PKD2L2 PKDREJ
6 cystic kidney disease 34.7 ALB PKD1 PKD2 PKD2L1 PKHD1 TMEM67
7 chronic kidney failure 34.5 ACE ALB COL4A5 CST3 PKD1 PKD2
8 polycystic kidney disease 3 with or without polycystic liver disease 34.2 PKD1 PKD2
9 nephronophthisis 33.7 CEP290 PKD1 PKD2 PKHD1 TMEM67 UMOD
10 end stage renal failure 33.5 ACE ALB COL4A5 CST3 PKD1 UMOD
11 hematuria, benign familial 33.4 COL4A4 COL4A5
12 polycystic liver disease 32.8 ALB PKD1 PKD2 PKHD1
13 caroli disease 32.7 PKD1 PKHD1
14 glomerulonephritis 32.6 ALB COL4A4 COL4A5
15 polycystic liver disease 1 with or without kidney cysts 32.6 PKD1 PKD2 PKHD1 UMOD
16 multicystic dysplastic kidney 31.9 PKD1 PKD2
17 nephronophthisis 19 31.6 TMEM67 UMOD
18 joubert syndrome 6 31.6 CEP290 TMEM67
19 liver disease 31.5 ALB PKD1 PKD2 PKHD1
20 hypertension, essential 31.2 ACE ALB COL4A5 CST3 PKD1 PKD2
21 congenital hepatic fibrosis 31.2 PKD1 PKHD1 TMEM67
22 pyelonephritis 31.0 ACE ALB UMOD
23 renal dysplasia, cystic 30.9 CEP290 PKD1
24 focal segmental glomerulosclerosis 30.8 ACE ALB COL4A4 COL4A5
25 interstitial nephritis 30.6 ACE ALB UMOD
26 hepatorenal syndrome 30.5 ACE ALB CST3
27 meckel syndrome, type 3 30.4 CEP290 TMEM67
28 acute kidney tubular necrosis 30.4 ALB CST3 UMOD
29 anti-basement membrane glomerulonephritis 30.0 COL4A4 COL4A5
30 oligohydramnios 30.0 ACE PKHD1 TMEM67
31 encephalocele 29.6 CEP290 TMEM67
32 medullary cystic kidney disease 1 12.6
33 autosomal dominant tubulointerstitial kidney disease due to umod mutations 12.6
34 autosomal dominant tubulointerstitial kidney disease 12.6
35 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.6
36 nephrolithiasis, x-linked recessive, with renal failure 12.5
37 medullary cystic kidney disease 2 12.5
38 iga nephropathy 1 12.4
39 polycystic kidney disease 5 12.4
40 ventriculomegaly with cystic kidney disease 12.4
41 autosomal dominant tubulointerstitial kidney disease due to muc1 mutations 12.4
42 bifid nose with or without anorectal and renal anomalies 12.4
43 iga nephropathy 3 12.4
44 polycystic kidney disease 6 with or without polycystic liver disease 12.4
45 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.3
46 polycystic kidney disease, infantile severe, with tuberous sclerosis 12.3
47 autoimmune interstitial lung, joint, and kidney disease 12.3
48 nephropathy with pretibial epidermolysis bullosa and deafness 12.3
49 autosomal dominant tubulointerstitial kidney disease due to ren mutations 12.3
50 autosomal dominant tubulointerstitial kidney disease, muc1-related 12.2

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hydronephrosis
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease
Sources

Symptoms & Phenotypes for Kidney Disease

About this section

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ACE CEP290 COL4A5 CST3 PKD1 PKD1L1
2 digestive/alimentary MP:0005381 9.8 ALB COL4A4 PKD1 PKD1L1 PKD2 PKHD1
3 liver/biliary system MP:0005370 9.7 ACE ALB CEP290 PKD1 PKD2 PKHD1
4 renal/urinary system MP:0005367 9.7 ACE ALB CEP290 COL4A4 COL4A5 PKD1
5 reproductive system MP:0005389 9.23 ACE CEP290 CST3 PKD1 PKD1L1 PKD1L2
Sources

Drugs & Therapeutics for Kidney Disease

About this section

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1656)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Perindopril Approved Phase 4,Phase 3 107133-36-8, 82834-16-0 107807
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198
3
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137862-53-4 60846
4
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
5
Pitavastatin Approved Phase 4,Phase 3,Phase 1 147511-69-1, 147526-32-7 5282452 6366718
6
Denosumab Approved Phase 4,Phase 3,Phase 2,Phase 1 615258-40-7
7 Menaquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1182-68-9
8
Phylloquinone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84-80-0
9
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
10
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
11
Fosinopril Approved Phase 4,Phase 3,Phase 2,Not Applicable 98048-97-6 55891
12
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
13
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
14
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
15
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
16
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
17
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
18
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 138402-11-6 3749
19
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 40466924 5362032
20
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
21
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
22
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
23
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
24
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
25
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
26
Parathyroid hormone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9002-64-6
27
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6493-05-6 4740
28
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
29
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-24-7, 144689-63-4 158781 130881
30
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144701-48-4 65999
31
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
32
tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1401-55-4
33
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
34
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
35
Iron Approved, Experimental Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6, 15438-31-0 27284 23925
36
Insulin glargine Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 160337-95-1
37
Insulin Lispro Approved Phase 4,Phase 3,Not Applicable 133107-64-9
38
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 141758-74-9 15991534
39
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1952-01-7, 52-01-7 5833
40
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
41
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
42
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4205-90-7 2803
43
Atenolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 29122-68-7 2249
44
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
45
Doxazosin Approved Phase 4,Phase 3,Not Applicable 74191-85-8 3157
46
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 54-31-9 3440
47
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120202-66-6, 113665-84-2 60606
48
Ticagrelor Approved Phase 4,Phase 3,Phase 1,Phase 2 274693-27-5 9871419
49
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
50
Alprostadil Approved, Investigational Phase 4 745-65-3 5280723 149351

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
2 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
3 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
4 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
5 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
6 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
7 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
8 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
9 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
10 Study Evaluating Denosumab on Bone and Vascular Metabolism in Osteoporotic Chronic Kidney Disease Unknown status NCT02792413 Phase 4 Denosumab;NaCl (placebo)
11 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
12 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
13 Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
14 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
15 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
16 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
17 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
18 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
19 Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement Unknown status NCT03121053 Phase 4 sodium bicarbonate;hypotone saline
20 Clinical Study of Treating Type 2 Diabetic Nephropathy With Alfacalcidol and Irbesartan Unknown status NCT03147677 Phase 4 Alfacalcidol;Irbesartan
21 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
22 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
23 Cholecalciferol Supplementation in Restless Leg Syndrome in Patients With Chronic Kidney Disease Unknown status NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
24 N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
25 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
26 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
27 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
28 Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
29 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
30 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
31 Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease Unknown status NCT02831062 Phase 4
32 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
33 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy Unknown status NCT02690883 Phase 4 Exenatide;Lispro
34 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
35 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
36 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
37 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
38 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
39 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
40 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
41 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
42 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
43 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
44 COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
45 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4 Alprostadil ï¹ control
46 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
47 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
48 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
49 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
50 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: kidney diseases

Sources

Genetic Tests for Kidney Disease

About this section

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Nephropathy 30
2 Abnormality of the Kidney 30
Sources

Anatomical Context for Kidney Disease

About this section

MalaCards organs/tissues related to Kidney Disease:

42
Kidney, Heart, Liver, Bone, Endothelial, Testes, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

20
The Kidney
Sources

Publications for Kidney Disease

About this section

Articles related to Kidney Disease:

(show top 50) (show all 13950)
# Title Authors Year
1
Adrenal crisis presented as acute onset of hypercalcemia and hyponatremia triggered by acute pyelonephritis in a patient with partial hypopituitarism and pre-dialysis chronic kidney disease. ( 30456557 )
2019
2
Chronic kidney disease and aging differentially diminish bone material and microarchitecture in C57Bl/6 mice. ( 31055118 )
2019
3
Regression of chronic kidney disease in a patient with AL amyloidosis: A case report
. ( 30935458 )
2019
4
Higher Incidence of BK Virus Nephropathy in Pediatric Kidney Allograft Recipients with Alport Syndrome. ( 30978953 )
2019
5
Molecular mechanisms underlying uremic toxin-related systemic disorders in chronic kidney disease: focused on β2-microglobulin-related amyloidosis and indoxyl sulfate-induced atherosclerosis-Oshima Award Address 2016. ( 29869756 )
2019
6
No Difference in Cognitive Dysfunction Among Patients with ANCA-Associated Vasculitis, Rheumatoid Arthritis or Chronic Kidney Disease. ( 31030697 )
2019
7
Risk of Ascending Aortic Aneurysm in Patients With Autosomal Dominant Polycystic Kidney Disease. ( 30477801 )
2019
8
Abdominal Aortic Aneurysm Associated with Polycystic Kidney Disease: Endovascular Aortic Repair and Renal Embolization. ( 30342219 )
2019
9
Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Deficiency in Vascular Smooth Muscle Cells Prevents Arteriovenous Fistula Failure Despite Chronic Kidney Disease. ( 30587058 )
2019
10
Membranous nephropathy caused by rheumatoid arthritis. ( 31037495 )
2019
11
Latent tuberculosis infection and non-infectious co-morbidities: Diabetes mellitus type 2, chronic kidney disease and rheumatoid arthritis. ( 30802622 )
2019
12
An interleukin-17 inhibitor successfully treated a complicated psoriasis and psoriatic arthritis patient with hepatitis B virus infection and end-stage kidney disease on hemodialysis. ( 30733983 )
2019
13
Comparison of incidence of acute kidney injury, chronic kidney disease and end-stage renal disease between atrial fibrillation and atrial flutter: real-world evidences from a propensity score-matched national cohort analysis. ( 31073825 )
2019
14
Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. ( 31073827 )
2019
15
Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMANâ„¢ device. ( 31092201 )
2019
16
Changes in renal function and occurrence of contrast-induced nephropathy after percutaneous coronary interventions in patients with atrial fibrillation treated with non-vitamin K oral anticoagulants or warfarin. ( 31043986 )
2019
17
Effectiveness and Safety of Rivaroxaban Versus Warfarin in Nonvalvular Atrial Fibrillation Patients with Severe Kidney Disease or Undergoing Hemodialysis. ( 31054829 )
2019
18
Risks of anticoagulation in patients with chronic kidney disease and atrial fibrillation: More than just bleeding? ( 31011695 )
2019
19
Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. ( 31011705 )
2019
20
Rho kinase activity and atrial fibrillation: insights from chronic kidney disease and dialysis patients. ( 30920496 )
2019
21
Response by Siontis et al to Letter Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States". ( 30883218 )
2019
22
Letter by Cheen Regarding Article, "Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States". ( 30883225 )
2019
23
Longitudinal kidney function trajectories predict major bleeding, hospitalization and death in patients with atrial fibrillation and chronic kidney disease. ( 30777405 )
2019
24
Short-Term Outcomes in Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: How Important Is Ethnicity? ( 30717613 )
2019
25
Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry. ( 30717616 )
2019
26
Case of psoriasis vulgaris with atrial fibrillation, heart failure and chronic kidney disease which were found accidentally through blood examination during apremilast treatment. ( 30663127 )
2019
27
Contrast-induced nephropathy is associated with new-onset atrial fibrillation in acute coronary syndrome after cardiac catheterization: Systemic review and meta-analysis. ( 30615229 )
2019
28
Chronic kidney disease predicts atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. ( 30650039 )
2019
29
Association of metabolic syndrome and chronic kidney disease with atrial fibrillation: A nationwide population-based study in Korea. ( 30578822 )
2019
30
Demystifying the Benefits and Harms of Anticoagulation for Atrial Fibrillation in Chronic Kidney Disease. ( 30593489 )
2019
31
Atrial Fibrillation: A New Risk Factor for Contrast-Induced Nephropathy. ( 30261741 )
2019
32
Uncertainty surrounds anticoagulation risks and benefits in patients with chronic kidney disease with atrial fibrillation. ( 30006370 )
2019
33
Clinical characteristics of autoimmune pancreatitis with IgG4 related kidney disease. ( 30826634 )
2019
34
Aortic Dissection Associated with Autosomal Dominant Polycystic Kidney Disease: A Case Report. ( 30806618 )
2019
35
A Rare Case Report of Emphysematous Cyst Infection in Autosomal Dominant Polycystic Kidney Disease. ( 30814802 )
2019
36
Autosomal dominant polycystic kidney disease. ( 30819518 )
2019
37
PKD1 Duplicated regions limit clinical Utility of Whole Exome Sequencing for Genetic Diagnosis of Autosomal Dominant Polycystic Kidney Disease. ( 30858458 )
2019
38
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. ( 30898339 )
2019
39
Long-term trajectory of kidney function in autosomal-dominant polycystic kidney disease. ( 30922668 )
2019
40
Bioelectrical impedance analysis as a nutritional assessment tool in Autosomal Dominant Polycystic Kidney Disease. ( 30947248 )
2019
41
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. ( 30951521 )
2019
42
Prostatic cyst in autosomal dominant polycystic kidney disease: unusual association. ( 30954962 )
2019
43
CT of Kidney Volume in Autosomal Dominant Polycystic Kidney Disease: Accuracy, Reproducibility, and Radiation Dose. ( 30964424 )
2019
44
Early Urinary Biomarkers in Pediatric Autosomal Dominant Polycystic Kidney Disease (ADPKD): No Evidence in the Interest of Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL). ( 30968008 )
2019
45
Mutation analyses by next-generation sequencing and multiplex ligation-dependent probe amplification in Japanese autosomal dominant polycystic kidney disease patients. ( 30989420 )
2019
46
Endothelin-1 as a therapeutic target in autosomal dominant polycystic kidney disease
. ( 30990410 )
2019
47
Subarachnoid Hemorrhage in Hospitalized Renal Transplant Recipients with Autosomal Dominant Polycystic Kidney Disease: A Nationwide Analysis. ( 30999564 )
2019
48
Uroflowmetry alterations in patients with autosomal dominant polycystic kidney disease. ( 31002123 )
2019
49
Splenic artery aneurysm in a patient of autosomal dominant polycystic kidney disease: beyond tenuous concomitance! ( 31005868 )
2019
50
Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model. ( 31014270 )
2019